Influence of waist circumference on the metabolic risk associated with impaired fasting glucose: Effect of weight loss after gastric bypass

Obesity Surgery

Volumn 17, Issue 5, 2007, Pages 585-591

  Gómez Ambrosi, Javier ^a,b   Pastor, Carlos ^a   Salvador, Javier ^a   Silva, Camilo ^a   Rotellar, Fernando ^a   Gil, M Jesús ^a   Catalán, Victoria ^a   Rodríguez, Amaia ^a   Cienfuegos, Javier A ^a   Frühbeck, Gema ^a  

^a UNIVERSITY CLINIC OF NAVARRA   (Spain)

^b UNIVERSITY OF NAVARRA   (Spain)

Author keywords

Cardiovascular risk factors; Impaired fasting glucose; QUICKI; Type 2 diabetes mellitus screening; Waist circumference; White blood cells

Indexed keywords

CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HOMOCYSTEINE;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; ATHEROGENESIS; BLOOD CELL COUNT; BODY MASS; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; IMPAIRED GLUCOSE TOLERANCE; INSULIN SENSITIVITY; MALE; METABOLIC DISORDER; MORBID OBESITY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK ASSESSMENT; RISK FACTOR; ROUX Y ANASTOMOSIS; STOMACH BYPASS; WAIST CIRCUMFERENCE; WEIGHT REDUCTION;

ADULT; BLOOD GLUCOSE; CHOLESTEROL; FEMALE; GASTRIC BYPASS; GLUCOSE INTOLERANCE; HUMANS; INSULIN RESISTANCE; MALE; OBESITY, MORBID; RISK FACTORS; WAIST-HIP RATIO; WEIGHT LOSS;

EID: 34250627224     PISSN: 09608923     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11695-007-9101-7     Document Type: Article

References (32)

1. Coutinho M, Gerstein HC, Wang Y et al. The relationship between glucose and incident cardiovascular events. A metaregression analysis of published data from 20 studies of 95,783 individuals followed for 12.4 years. Diabetes Care 1999; 22: 233-40.
2. Fernández-Real JM, Ricart W. Insulin resistance and chronic cardiovascular inflammatory syndrome. Endocr Rev 2003; 24: 278-301.
3. Genuth S, Alberti KG, Bennett P et al. Follow-up report on the diagnosis of diabetes mellitus. Diabetes Care 2003; 26: 3160-7.
4. Phillips LS, Weintraub WS, Ziemer DC et al. All prediabetes is not the same: metabolic and vascular risks of impaired fasting glucose at 100 versus 110 mg/dl: the Screening for Impaired Glucose Tolerance study 1 (SIGT 1). Diabetes Care 2006; 29: 1405-7.
5. Wahrenberg H, Hertel K, Leijonhufvud BM et al. Use of waist circumference to predict insulin resistance: retrospective study. BMJ 2005; 330: 1363-4.
6. Seidell JC, Perusse L, Despres JP et al. Waist and hip circumferences have independent and opposite effects on cardiovascular disease risk factors: the Quebec Family Study. Am J Clin Nutr 2001; 74: 315-21.
7. Despres JP. Is visceral obesity the cause of the metabolic syndrome? Ann Med 2006; 38: 52-63.
8. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y - 500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000; 10: 233-9.
9. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol 1969; 22: 158-61.
10. Katz A, Nambi SS, Mather K et al. Quantitative insulin sensitivity check index: a simple, accurate method for assessing insulin sensitivity in humans. J Clin Endocrinol Metab 2000; 85: 2402-10.
11. Gómez-Ambrosi J, Salvador J, Páramo JA et al. Involvement of leptin in the association between percentage of body fat and cardiovascular risk factors. Clin Biochem 2002; 35: 315-20.
12. Friedewald WT, Levy RI, Fredrickson S. Estimation of the concentration of low density lipoprotein cholesterol in plasma, without the use of preparative ultra-centrifuge. Clin Chem 1972; 18: 499-502.
13. Clauss A. Gerinnungsphysiologische Schnellmethode zur Bestimmung des Fibrinogens. Acta Haematol 1957; 17: 237-40.
14. Grundy SM. Metabolic syndrome: connecting and reconciling cardiovascular and diabetes worlds. J Am Coll Cardiol 2006; 47: 1093-100.
15. Ridker PM, Stampfer MJ, Rifai N. Novel risk factors for systemic atherosclerosis: a comparison of C-reactive protein, fibrinogen, homocysteine, lipoprotein(a), and standard cholesterol screening as predictors of peripheral arterial disease. JAMA 2001; 285: 2481-5.
16. Guthikonda S, Haynes WG. Homocysteine: role and implications in atherosclerosis. Curr Atheroscler Rep 2006; 8: 100-6.
17. Mertens I, Verrijken A, Michiels JJ et al. Among inflammation and coagulation markers, PAI-1 is a true component of the metabolic syndrome. Int J Obes 2006; 30: 1308-14.
18. Ohshita K, Yamane K, Hanafusa M et al. Elevated white blood cell count in subjects with impaired glucose tolerance. Diabetes Care 2004; 27: 491-6.
19. Danesh J, Collins R, Appleby P et al. Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: meta-analyses of prospective studies. JAMA 1998; 279: 1477-82.
20. Tong PC, Lee KF, So WY et al. White blood cell count is associated with macro- and microvascular complications in Chinese patients with type 2 diabetes. Diabetes Care 2004; 27: 216-22.
21. Lee WJ, Wang W, Chen TC et al. Clinical significance of central obesity in laparoscopic bariatric surgery. Obes Surg 2003; 13: 921-5.
22. Dixon JB, O'Brien PE. Obesity and the white blood cell count: changes with sustained weight loss. Obes Surg 2006; 16: 251-7.
23. Poirier P, Giles TD, Bray GA et al. Obesity and cardiovascular disease: pathophysiology, evaluation, and effect of weight loss: an update of the 1997 American Heart Association Scientific Statement on Obesity and Heart Disease from the Obesity Committee of the Council on Nutrition, Physical Activity, and Metabolism. Circulation 2006; 113: 898-918.
24. Frühbeck G. The adipose tissue as a source of vasoactive factors. Curr Med Chem - Cardiovasc Hematol Agents 2004; 2: 197-208.
25. Matsuzawa Y. Therapy Insight: adipocytokines in metabolic syndrome and related cardiovascular disease. Nat Clin Pract Cardiovasc Med 2006; 3: 35-42.
26. Patriti A, Facchiano E, Sanna A et al. The enteroinsular axis and the recovery from type 2 diabetes after bariatric surgery. Obes Surg 2004; 14: 840-8.
27. Sjöström L, Lindroos AK, Peltonen M et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N Engl J Med 2004; 351: 2683-93.
28. Frühbeck G, Diez-Caballero A, Gil MJ et al. The decrease in plasma ghrelin concentrations following bariatric surgery depends on the functional integrity of the fundus. Obes Surg 2004; 14: 606-12.
29. Gómez-Ambrosi J, Salvador J, Rotellar F et al. Increased serum amyloid A concentrations in morbid obesity decrease after gastric bypass. Obes Surg 2006; 16: 262-9.
30. Buchwald H, Avidor Y, Braunwald E et al. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004; 292: 1724-37.
31. fm to measure insulin resistance in morbid obesity. Obes Surg 2006; 16: 549-53.
32. Torquati A, Lutfi R, Abumrad N et al. Is Roux-en-Y gastric bypass surgery the most effective treatment for type 2 diabetes mellitus in morbidly obese patients? J Gastrointest Surg 2005; 9: 1112-6.